中英合作 新加坡乐和彩最新资料生物科技(集团)有限公司

新加坡乐和彩最新资料生物科技有限公司(集团)是专注于大肠杆菌药系列产品的研发、生产、销售为一体的兽用药品制造服务商。公司生产基地坐落于千年古都安阳市新加坡乐和彩最新资料工业园,公司总投资5000万元,占地面积80亩,一期工程建成了粉散剂、预混剂、消毒液GMP标准化生产线。二期工程建成了口服液、中药提取物等高标准生产线。三期工程饲料添加剂及生物制品等高标准生产线即将开工建设,建成后三条融合全国先进工艺的生产线将进一步完善各品类的产品布局。

 

专注打造大肠杆菌药是新加坡乐和彩最新资料集团13年以来坚持的品牌发展战略,至2017年,大肠杆菌药系列产品销售额占集团总销售额的60%以上,初步形成了以大肠杆菌药系列产品为主,以肠道类、综合保健类为辅的产品构架,新加坡乐和彩最新资料集团预计2018年大肠杆菌药系列产品的销售额将取得进一步突破。

 
为了进一步提升大肠杆菌药中国领先品牌的核心竞争力,自2009年起,新加坡乐和彩最新资料集团每年投入3%-5%的销售额用于产品研发,在国外以英国利物浦大学(liverpool.uk)兽医学院为窗口吸收国际前沿兽医新技术,在国内初步组建了以河南农大、山东农大、华中农大、河南牧业经济学院等高等农牧院校教授、研究生为主20余人的研发团队,正在申报的专利三项,已立项的国家三类新兽药2个,已基本确立了以中药及生物制品等防治大肠杆菌病、提高机体免疫力、绿色无残留的产品为主要研发方向,现已组建在此研发方向上的国家级生物工程企业研发中心。
 
在未来,我们力争成为中国较具影响力的兽药研发生产企业。新加坡乐和彩最新资料集团将秉承“自强不息、厚德载物”的企业精神,与企业员工以及同行企业互生共赢,全力整合畜牧业资源,适时拓展产业链条,增强资本优势,形成规模效益,必将会更好、更健康的服务于中国畜牧行业,以带动更多人同赴富裕!
 
China-UK cooperation oup biological technology (Group) Co., Ltd.

OUP Biological Technology Co., Ltd. (Group) is a research and development, the country's first focus on Escherichia coli drug products production, sales as one of the veterinary drug manufacturing service providers. Company production base is located in industrial park of Anyang OUP Millennium ancient capital, the company a total investment of 50000000 yuan, covers an area of 80 mu, the first phase of the project completed powder, premix, disinfection liquid GMP standard production line. The two phase of the project is completed, the oral liquid herbal extracts such as high standard production line. The three phase of the project of feed additive and biological products such as high standard production line is about to start construction, after the completion of the nation's leading three fusion process production line will further improve the various categories of products distribution.

 
Focus to build China's lead brand is Escherichia coli drug OUP group since 8 years adhere to the brand development strategy, to 2012, Escherichia coli drug products accounted for 60% of the group's total sales, the initial formation of the Escherichia coli drug series products, product structure, comprehensive care to intestinal type auxiliary OUP group, is expected in 2015 Escherichia coli drug products sales will exceed 100000000 yuan.
 
In order to further enhance the core competitiveness of Escherichia coli drug China's first brand, since 2009, annual investment OUP group 3%-5% sales for product development, in foreign countries to the University of Liverpool (liverpool.uk) School of veterinary medicine for the window to absorb international advanced veterinary technology at home, the initial formation of the Henan agricultural University, Shandong Agricultural University, Huazhong Agricultural University, Henan Institute of animal husbandry economy of higher agricultural colleges Professor, graduate student 20 person R & D team, was declared the three patents, three class new veterinary drug has been approved to 2 countries, has been basically established the Chinese medicine and biological products such as prevention of colibacillosis, improve immunity, green no residual products as the main direction of research and development, set up a National Biotechnology R & D center on the development direction of the now.
 
In the future, we will strive to become China's most influential veterinary medicine R & D and production enterprises. OUP group will be adhering to the "unremitting self-improvement, social commitment" spirit of enterprise, and enterprise employees and competitors alternate win-win, full integration of animal husbandry resources, to expand the industrial chain, enhance the capital advantage, economies of scale, will be better, more health services in China animal husbandry industry, to bring more people to the rich!
新加坡乐和彩最新资料资质: